CN101200752B - Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor - Google Patents
Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor Download PDFInfo
- Publication number
- CN101200752B CN101200752B CN200610128390A CN200610128390A CN101200752B CN 101200752 B CN101200752 B CN 101200752B CN 200610128390 A CN200610128390 A CN 200610128390A CN 200610128390 A CN200610128390 A CN 200610128390A CN 101200752 B CN101200752 B CN 101200752B
- Authority
- CN
- China
- Prior art keywords
- chloroform
- compound
- eburicoic acid
- methanol
- volume ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Abstract
The invention provides a method of separating and preparing eburicoic acid compound by the fermentation liquid of long hair follicle fungus. A plate transgenic shaking flask liquid culture method is adopted. Firstly, glucose, peeled potatoes, MgSO4, KH2PO4, VB1 and water are mixed and stirred to prepare culture medium; then, culturing the culture medium to be fermented to obtain fermentation liquor; extracting the fermentation liquid to obtain an extract; drying mycelium and extracting with chloroform-methanol to obtain extract; combining the two extracts for the column chromatography separation and the chloroform-methanol gradient elution; a group of mixtures containing the compound are obtained at the chloroform-methanol elution part after the repeated column chromatography; petroleum ether-acetone elution is adopted to separate the mixtures to obtain a compound eburicoic acid pure product. The invention can solves the raw material source problem for developing the eburicoic acid into raw medicine of drugs for curing human leukemia. And the invention has the advantages of mild culture conditions, easy medium preparation, short fermentation tie, large yield, easy production in large scale, etc.
Description
Technical field
The present invention relates to the become mildewed fermented liquid of bag hole bacterium of a kind of utilization and separate the method for preparing the eburicoic acid compound.
Background technology
According to document L.Francisco, Q.Jose, R.Augusto, et al., Lanostanoid triterpenes fromLaetiporus sulphureus and apoptosis induction on HL-60 human myeloid leukemiacells.J.Nat.Prod., 2004,67 (12), 2008. record, the compound eburicoic acid is induced people HL-60 bone marrow leukemia cells effect of apoptosis, its IC
50=23-27 μ M, 3 beta-hydroxy acetylize eburicoic acids show the strongest people HL-60 bone marrow leukemia cells effect of apoptosis (IC that induces
50=13-15 μ M).Its chemical structure is as follows:
In view of this compound and acetylate thereof are being induced the fine activity that shows aspect the people HL-60 bone marrow leukemia cells apoptosis, the work that eburicoic acid is developed to the bulk drug of treatment human leukemia medicine has the value of further further investigation.
The bag hole bacterium (Trametes versatillis.Berk) that becomes mildewed is polyporaceae (Polyporaceae) fungi, and sporophore is general medium big, keratin, and 3-7cm * 4-10cm, thick 2-3mm, grey is become mildewed on the surface.The bacterial context near-white, thick 2-3mm.The long 7mm of tube, wall is thin, and nozzle diameter 0.5-1.5mm is polygonal, microscler, grey.Be born on the rotten wood of needle or broad-leaf forest, mainly be distributed in ground such as Hebei, Anhui, Jiangsu, Jiangxi, Hainan, Guangdong, Yunnan.So far, become mildewed bag hole mushroom entity and fermented liquid chemical ingredients all do not appeared in the newspapers.We find that in bag hole bacterium process is become mildewed in research this bacterium is a bacterial classification that well produces eburicoic acid, we utilize conventional separation means that the fermented liquid of the bag hole bacterium that becomes mildewed has been carried out isolation identification, result of study shows that eburicoic acid is a main component, mainly from mycelium (its content account for mycelium dry weight 1%).Result of study shows that this bacterial classification produces mycelia many (every liter of fermented liquid can produce exsiccant mycelium 8 grams), fermentation time short (14 days).Therefore the optimization work that carries on culture medium prescription has very high researching value and using value.
Summary of the invention
The purpose of this invention is to provide the become mildewed fermented liquid of bag hole bacterium of a kind of utilization and separate the method for preparing the eburicoic acid compound.
For achieving the above object, the technical solution used in the present invention is: the become mildewed fermented liquid of bag hole bacterium of a kind of utilization separates the method for preparing the eburicoic acid compound, makes by following step operation: adopt plate to change the method for shaking bottle liquid culture, at first use glucose, peeled potatoes, MgSO
4, KH
2PO
4, VB
1Add water mixing stirring and make substratum; Get fermented liquid in cultivation and fermentation in the dark then, be divided into two parts of fermented liquid and mycelium; Extractive fermentation liquid obtains medicinal extract; The oven dry mycelium obtains medicinal extract with chloroform-methanol extraction; Merge two portions medicinal extract after TLC detects, last column chromatography for separation is with chloroform-methanol system gradient elution; Obtain containing one group of mixture of compound eburicoic acid in chloroform-methanol wash-out part through column chromatography repeatedly; This mixture adopts sherwood oil-acetone wash-out to separate, and obtains the pure product of compound eburicoic acid.
The inventive method can be made by following concrete steps operation: adopt plate to change the method for shaking bottle liquid culture, at first use glucose 15-25g, peeled potatoes 180-250g, MgSO
41-2g, KH
2PO
42.5-3.5g, VB
18-12mg adds water and mixes to 1000ml and make substratum; Then in temperature: 20-32 ℃, rotating speed: under the 150-200r/min condition in the dark after cultivation and fermentation 12-20 days altogether fermented liquid 8-11 liter, be divided into two parts of fermented liquid and mycelium; Fermented liquid obtains 1.8-2.4 gram medicinal extract with ethyl acetate extraction twice; Mycelium weight in wet base 400-450 gram, the heavy 70-85 gram in oven dry back; Mycelium after the oven dry is the chloroform-methanol extraction twice of 30-70: 70-30 with the volume ratio, obtains the medicinal extract of 5.5-6.5 gram altogether; Merge two portions medicinal extract after TLC detects, last silicagel column separates, and is the chloroform-methanol system gradient elution of 100-80: 0-20 with the volume ratio, and every 100ml is a stream part; Obtain containing one group of mixture of compound eburicoic acid in the chloroform-methanol wash-out part that with the volume ratio is 99-90: 1-10 through column chromatography repeatedly; It is sherwood oil-acetone wash-out separation of 75-65: 25-35 that this mixture adopts volume ratio, obtains the pure product of compound eburicoic acid.
Adopt technical solutions according to the invention can solve the raw material sources problem of eburicoic acid for the bulk drug that eburicoic acid is developed to treatment human leukemia medicine, this technology has the culture condition gentleness, the substratum preparation is simple, fermentation time short, output big, be easy to advantage such as scale operation.
Embodiment
Example 1
Adopt plate to change the method for shaking bottle liquid culture, at first use glucose 20g, peeled potatoes 200g, MgSO
41.5g, KH
2PO
43g, VB
110mg adds water and mixes to 1000ml and make substratum; Then in temperature: 25 ℃, rotating speed: under the 170r/min condition in cultivation and fermentation in the dark after 15 days altogether 10 liters of fermented liquids, be divided into two parts of fermented liquid and mycelium; Fermented liquid obtains 2 gram medicinal extract with ethyl acetate extraction twice; Mycelium weight in wet base 420 grams, the oven dry back weighs 80 grams; The exsiccant mycelium extracts twice with chloroform-methanol (volume ratio 40: 60), obtains the medicinal extract of 6 grams altogether; Merge two portions medicinal extract after TLC detects, last silicagel column separates, and is the chloroform-methanol system gradient elution of 100-80: 0-20 with the volume ratio, and every 100ml is a stream part; Obtain containing one group of mixture of compound eburicoic acid in chloroform-methanol (volume ratio 95: 5) wash-out part through column chromatography repeatedly; This mixture adopts sherwood oil-acetone (volume ratio 70: 30) wash-out to separate, and obtains the pure product of compound eburicoic acid.
Example 2
Adopt plate to change the method for shaking bottle liquid culture, at first use glucose 15g, peeled potatoes 180g, MgSO
41.0g, KH
2PO
42.5g, VB
18mg adds water and mixes to 1000ml and make substratum; Then in temperature: 20 ℃, rotating speed: under the 150r/min condition in cultivation and fermentation in the dark after 12 days altogether about 10 liters of fermented liquid, be divided into two parts of fermented liquid and mycelium; Fermented liquid obtains 1.8 gram medicinal extract with ethyl acetate extraction twice; Mycelium weight in wet base 400 grams, the oven dry back weighs 75 grams; The exsiccant mycelium extracts twice with chloroform-methanol (volume ratio 70: 30), obtains the medicinal extract of 5.5 grams altogether; Merge two portions medicinal extract after TLC detects, last silicagel column separates, and is the chloroform-methanol system gradient elution of 100-80: 0-20 with the volume ratio, and every 100ml is a stream part; Obtain containing one group of mixture of compound eburicoic acid in chloroform-methanol (volume ratio 90: 10) wash-out part through column chromatography repeatedly; This mixture adopts sherwood oil-acetone (volume ratio 75: 25) wash-out to separate, and obtains the pure product of compound eburicoic acid.
Example 3
Adopt plate to change the method for shaking bottle liquid culture, at first use glucose 25g, peeled potatoes 220g, MgSO
42.0g, KH
2PO
43.2g, VB
112mg adds water and mixes to 1000ml and make substratum; Then in temperature: 32 ℃, rotating speed: under the 200r/min condition in cultivation and fermentation in the dark after 18 days altogether 12 liters of fermented liquids, be divided into two parts of fermented liquid and mycelium; Fermented liquid obtains 2.5 gram medicinal extract with ethyl acetate extraction twice; Mycelium weight in wet base 450 grams, the oven dry back weighs 82 grams; The exsiccant mycelium extracts twice with chloroform-methanol (volume ratio 65: 35), obtains the medicinal extract of 6.5 grams altogether; Merge two portions medicinal extract after TLC detects, last silicagel column separates, and is the chloroform-methanol system gradient elution of 100-80: 0-20 with the volume ratio, and every 100ml is a stream part; Obtain containing one group of mixture of compound eburicoic acid in chloroform-methanol (volume ratio 92: 8) wash-out part through column chromatography repeatedly; This mixture adopts sherwood oil-acetone (volume ratio 65: 35) wash-out to separate, and obtains the pure product of compound eburicoic acid.
Respectively the pure product of gained compound eburicoic acid in the example 1,2,3 are carried out physics and chemistry and spectral data analysis, the result is as follows:
Eburicoic acid, C
31H
50O
3, colourless needle, m.p.:274-275 ℃, [α]
D 26=+39 ° of (pridine; C=1.0).EI-MS?m/z(％)：470(14，[M]
+)，455(30)，437(100)，419(48)，55(88)。HR-ESI-MS:470.3712 (calculated value is 470.3759).
1H-NMR(C
5D
5N，400MHz)：δ1.03(3H，d，J＝7.0Hz，H-26)，1.04(3H，d，J＝7.0Hz，H-27)，1.04(6H，br.s?H-18，H-26)，1.08(3H，s，H-19)，1.10(3H，s，H-30)，1.25(3H，s，H-28)，2.29(1H，m，H-25)，2.66(1H，t，J＝11.3Hz，H-20)，3.45(1H，m，H-3)，4.90(1H，s，H-31a)，4.94(1H，s，H-31b)。
13C-NMR(C
5D
5N，100MHz)：δ36.1(t，C-1)，28.7(t，C-2)，78.0(d，C-3)，39.5(s，C-4)，50.9(d，C-5)，18.7(t，C-6)，28.7(t，C-7)，135.2(s，C-8)，134.3(s，C-9)，37.4(s，C-10)，21.3(t，C-11)，29.4(t，C-12)，44.9(s，C-13)，49.9(s，C-14)，30.9(t，C-15)，27.5(t，C-16)，47.7(d，C-17)，16.3(q，C-18)，19.4(q，C-19)，49.2(d，C-20)，178.6(s，C-21)，31.8(t，C-22)，32.8(t，C-23)，155.9(s，C-24)，34.2(d，C-25)，22.0(q，C-26)，21.9(q，C-27)，28.6(q，C-28)，16.4(q，C-29)，24.5(q，C-30)，107.0(t，C-31)。Above data and document T.Tai, A.Akahori, T.Shingu, Triterpenes of Poria cocos.Phytochemistry, record value unanimity in 1993,32,1239..
Claims (1)
1. the become mildewed fermented liquid of bag hole bacterium of a utilization separates the method for preparing the eburicoic acid compound, it is characterized in that making: adopt plate to change the method for shaking bottle liquid culture by following concrete steps operation, at first use glucose 15-25g, peeled potatoes 180-250g, MgSO
41-2g, KH
2PO
42.5-3.5g, VB
18-12mg adds water and mixes to 1000ml and make substratum; Then in temperature: 20-32 ℃, rotating speed: under the 150-200r/min condition in the dark after cultivation and fermentation 12-20 days altogether fermented liquid 8-11 liter, be divided into two parts of fermented liquid and mycelium; Fermented liquid obtains 1.8-2.4 gram medicinal extract with ethyl acetate extraction twice; Mycelium weight in wet base 400-450 gram, the heavy 70-85 gram in oven dry back; Mycelium after the oven dry is the chloroform-methanol extraction twice of 30-70: 70-30 with the volume ratio, obtains the medicinal extract of 5.5-6.5 gram altogether; Merge two portions medicinal extract after TLC detects, last silicagel column separates, and is the chloroform-methanol system gradient elution of 100-80: 0-20 with the volume ratio, and every 100ml is a stream part; Obtain containing one group of mixture of compound eburicoic acid in the chloroform-methanol wash-out part that with the volume ratio is 99-90: 1-10 through column chromatography repeatedly; The employing volume ratio is that sherwood oil-acetone wash-out of 75-65: 25-35 separates, and obtains the pure product of compound eburicoic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610128390A CN101200752B (en) | 2006-12-15 | 2006-12-15 | Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200610128390A CN101200752B (en) | 2006-12-15 | 2006-12-15 | Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101200752A CN101200752A (en) | 2008-06-18 |
| CN101200752B true CN101200752B (en) | 2010-05-12 |
Family
ID=39516102
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200610128390A Expired - Fee Related CN101200752B (en) | 2006-12-15 | 2006-12-15 | Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101200752B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3442916A (en) * | 1967-06-27 | 1969-05-06 | Squibb & Sons Inc | Isolation of eburicoic acid |
| US20040086580A1 (en) * | 2002-10-21 | 2004-05-06 | Tripp Matthew L. | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
-
2006
- 2006-12-15 CN CN200610128390A patent/CN101200752B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3442916A (en) * | 1967-06-27 | 1969-05-06 | Squibb & Sons Inc | Isolation of eburicoic acid |
| US20040086580A1 (en) * | 2002-10-21 | 2004-05-06 | Tripp Matthew L. | Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response |
Non-Patent Citations (7)
| Title |
|---|
| J.T.Pinhey.Extraction of Fungi. I.The Constrituent of Trametes.LilacinoGilva.Aust.J.Chem23.1970,232141-2146. * |
| 刘吉开.一些引人注目的药用天然产物.化学通报 3.1996,(3),15-19. |
| 刘吉开.一些引人注目的药用天然产物.化学通报 3.1996,(3),15-19. * |
| 刘吉开等.高等真菌次生代谢产物及其生物活性.中草药34 1.2003,34(1),84-86. |
| 刘吉开等.高等真菌次生代谢产物及其生物活性.中草药34 1.2003,34(1),84-86. * |
| 陈志辉等.两株多孔菌属担子菌菌丝体中的三萜成分.热带亚热带植物学报13 5.2005,13(5),399-402. |
| 陈志辉等.两株多孔菌属担子菌菌丝体中的三萜成分.热带亚热带植物学报13 5.2005,13(5),399-402. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101200752A (en) | 2008-06-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105648021B (en) | The preparation method of ginseng rare saponin(e C-K, F1 and four kinds of isomers ginsengenins | |
| CN104894204B (en) | The method that microbial enzyme conversion ginsenoside prepares the rare saponin(e of ginseng | |
| CN104694401B (en) | Penicillium viridicatum strain and the method that ergosterol peroxide is produced with it | |
| Dissanayake et al. | Cultivated maitake mushroom demonstrated functional food quality as determined by in vitro bioassays | |
| Isaka et al. | Lanostane triterpenoids from cultivated fruiting bodies of the wood-rot basidiomycete Ganoderma casuarinicola | |
| Lee et al. | 24-Ethylcholesta-4, 24 (28)-dien-3, 6-dione from Osmanthus fragrans var. aurantiacus flowers inhibits the growth of human colon cancer cell line, HCT-116 | |
| CN104311623B (en) | A kind of Sasanguasaponin C by name 1with Sasanguasaponin C 2pentacyclic triterpenoid and preparation method thereof and application | |
| CN104327148A (en) | Compounds with antitumor activity, and preparation method and application thereof | |
| CN101200752B (en) | Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor | |
| CN104262443B (en) | The preparation method and application of polyhydroxy sterol class monomeric compound | |
| CN104151390B (en) | Method and the application thereof of preparing Usu methyl esters is separated from dracocephalum heterophyllum | |
| Kang et al. | Studies on the constituents of the mycelia produced from fermented culture of Flammulina velutipes (W. Curt.: Fr.) Singer (Agaricomycetideae) | |
| CN112898373B (en) | Pentacyclic triterpenoid and preparation method and application thereof | |
| CN105037470B (en) | A kind of triterpene compound and preparation method thereof and medical usage | |
| CN107556358A (en) | Promote blood coagulation Cordyceps militaris active ingredient and its purification methods and uses | |
| CN107474092A (en) | A kind of straw mushroom fructification active component and its application | |
| CN107474027A (en) | The propionic acid of straw mushroom fructification active component 2 (5H) furanone 4 and application | |
| TW201803571A (en) | Cordyceps militaris extract for anti-inflammation and anti-proliferation against human liver cancer cell lines, and its preparation method | |
| CN109439718B (en) | Preparation of rare ginsenoside Rk3Method (2) | |
| Xu et al. | Secondary metabolites of Volvariella bombycina and their inhibitory effects on melanogenesis | |
| CN105330713B (en) | 3beta-acetoxyl ginsenoside F1 and extraction method and medicine application thereof | |
| CN111732624A (en) | New steroid saponin compound, preparation method thereof and application thereof in preparing medicament for treating type 2 diabetes | |
| CN106117294B (en) | The root of gansui alkane type triterpenoid Phellochin F compounds extracted in a kind of CORTEX PHELLODENDRI CHINENSE fruit and its application | |
| CN105434442A (en) | Synsepalum dulcificum leaf extract and application of same in preparation of drugs or health products used for treating diabetes or hyperlipidemia | |
| CN101333238B (en) | Triterpene compounds separated from seed of cowherb of Chinese traditional medicine and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Assignee: Anhui Haixin Traditional Chinese Medicine (TCM) Co., Ltd. Assignor: He'nan Agricultural University Contract record no.: 2011340000007 Denomination of invention: Method for separation and preparation of eburicoic acid compound by using hirschioporus versatilis fermentation liquor Granted publication date: 20100512 License type: Exclusive License Open date: 20080618 Record date: 20110309 |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20100512 Termination date: 20111215 |